KRAS and non-small cell lung carcinoma: NTRK1 gene rearrangements in NSCLC were first described in 2013 among a subset of patients with NSCLC with adenocarcinoma histology and no detectable EGFR, KRAS, ALK or ROS1 alterations (3/91; 3.3%) [80].